Zinbryta Approval History
- FDA approved: Yes (First approved May 27th, 2016)
- Brand name: Zinbryta
- Generic name: daclizumab
- Dosage form: Injection
- Company: Biogen
- Treatment for: Multiple Sclerosis
Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Development History and FDA Approval Process for Zinbryta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.